IDO1 and melanoma: Although the phase I/II clinical trials of epacadostat, a specific IDO1 inhibitor, in combination with immune checkpoint blockade, showed some promise in advanced malignant melanoma patients [71], the phase III clinical study failed to show improvement in progression-free survival or overall survival in metastatic melanoma patients [72].